News

SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford

23 May, 2024

SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

7 December, 2023

SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

20 September, 2023
SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses
20 March, 2023
SpyBiotech Appoints Industry Veteran Eddie Gray as Chair of its Board of Directors

13 February, 2023

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

12 July, 2022

A study using SpyBiotech’s vaccine technology shows its potential against Covid-19 and other Coronaviruses

29 April, 2022

SpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific team

16 November, 2021

SpyBiotech featured in The Guardian Value of Vaccines supplement
25 June, 2021

SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor

8 March, 2021

SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman

10 February, 2021

Study from Scripps using SpyTag/SpyCatcher for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development

8 October, 2020

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

8 September 2020

Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs

7 Sep 2020

Scroll to Top